Intrinsiqs

Is Supernus Pharmaceuticals, Inc. overvalued?

Supernus Pharmaceuticals, Inc. (SUPN) looks undervalued — trading about 60% below its fair value.

Undervalued
Current price $47.72 Fair value $76.55
Price
$47.72
Fair value
$76.55
Current P/E
13.9
Normal P/E
22.3
Market cap
$2.77B
Dividend yield
0.0%
Return on equity
-10.4%
Sector
Healthcare

See the full interactive analysis →

Fair value compares SUPN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.UNH UnitedHealth Group IncorporatedRHHBY Roche Holding AGMRK Merck & Co., Inc.